DSGN trades 174.6% below Wall Street's consensus target of $26.00.
Last 12 months price action with 12-month analyst target path
The base valuation assumes DSGN achieves its forward estimates and maintains a stable P/E multiple of historical averagesx. This scenario reflects the blended consensus of 7 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
As of November 19, 2026, Design Therapeutics, Inc. (DSGN) has a Wall Street consensus price target of $26.00, based on estimates from 7 covering analysts. With the stock currently trading at $9.47, this represents a potential upside of +174.6%. The company has a market capitalization of $591M.
Analyst price targets range from a low of $26.00 to a high of $26.00, representing a 0% spread in expectations. The median target of $26.00 aligns closely with the consensus average. The tight target dispersion indicates high conviction among analysts.
The current analyst consensus rating is Buy, with 4 analysts rating the stock as a Buy or Strong Buy,3 rating it Hold, and 0 rating it Sell or Strong Sell. The positive sentiment balance indicates moderate optimism about the stock prospects.
From a valuation perspective, DSGN trades at a trailing P/E of -8.1x. Analysts expect EPS to grow -12.0% over the next year.
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
FULCFulcrum Therapeutics, Inc. | $201M | $3.72 | $3.60 | -3.2% | Buy | — | 17 |
IMVTImmunovant, Inc. | $6.8B | $33.17 | $40.00 | +20.6% | Buy | — | 23 |
ARQTArcutis Biotherapeutics, Inc. | $3.5B | $27.61 | $41.80 | +51.4% | Buy | 66.9x | 12 |
BEAMBeam Therapeutics Inc. | $2.2B | $21.01 | $66.00 | +214.1% | Buy | — | 28 |
EDITEditas Medicine, Inc. | $272M | $1.77 | $5.50 | +210.7% | Buy | — | 26 |
CRSPCRISPR Therapeutics AG | $3.9B | $40.19 | $64.14 | +59.6% | Buy | — | 38 |
NTLAIntellia Therapeutics, Inc. | $1.1B | $9.77 | $20.71 | +112.0% | Buy | — | 39 |
PRMEPrime Medicine, Inc. | $690M | $3.82 | $7.50 | +96.3% | Buy | — | 10 |
ILMNIllumina, Inc. | $31.8B | $210.01 | $252.73 | +20.3% | Buy | 38.8x | 50 |
TMOThermo Fisher Scientific Inc. | $257.4B | $692.74 | $694.27 | +0.2% | Buy | 27.4x | 43 |
Quick answers to the most common questions about buying DSGN stock.
The consensus Wall Street price target for DSGN is $26, representing 174.6% upside from the current price of $9.47. With 7 analysts covering the stock, this strong upside suggests significant value not yet reflected in today's share price.
DSGN has a consensus rating of "Buy" based on 7 Wall Street analysts. The rating breakdown is predominantly bullish, with 4 Buy/Strong Buy ratings. The consensus 12-month price target of $26 implies 174.6% upside from current levels.
DSGN's current price is $9.47 with a consensus target of $26 (174.6% implied move). Analyst estimates suggest the stock is undervalued at current levels.
The most bullish Wall Street analyst has a price target of $26 for DSGN, while the most conservative target is $26. The consensus of $26 represents the median expectation. These targets typically reflect 12-month expectations.
DSGN is moderately covered, with 7 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 4 have Buy ratings, 3 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month DSGN stock forecast based on 7 Wall Street analysts shows a consensus price target of $26, with estimates ranging from $26 (bear case) to $26 (bull case). The median consensus rating is "Buy".
Wall Street analysts are very optimistic on DSGN, with a "Buy" consensus rating and $26 price target (174.6% upside). 4 of 7 analysts rate it Buy or Strong Buy. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
DSGN analyst price targets range from $26 to $26, a 0% tight range reflecting strong analyst consensus. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $26 consensus represents the middle ground.
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.